Liposomal Bupivacaine vs Peripheral Nerve Block
Overview
- Phase
- Phase 4
- Intervention
- Liposomal bupivacaine
- Conditions
- Pain, Acute
- Sponsor
- Geisinger Clinic
- Enrollment
- 1
- Locations
- 1
- Primary Endpoint
- Visual Analog Scale Pain Score
- Status
- Terminated
- Last Updated
- 3 years ago
Overview
Brief Summary
Liposomal bupivacaine has gained interest in recent literature for its potential to be an effective adjunct to other pain control modalities in a multi-modal approach to post-operative pain control. The goal of this investigation is to compare the efficacy of local administration of liposomal bupivacaine versus the efficacy of a peripheral nerve block in terms of post-operative pain scores after elective ankle and hindfoot surgery. The investigators hypothesize that there will not be a significant difference in the pain scores of these two groups in opioid naïve patients.
Detailed Description
Liposomal bupivacaine has gained interest in recent literature for its potential to be an effective adjunct to other pain control modalities in a multi-modal approach to post-operative pain control. Liposomal bupivacaine is an analgesic that is suspended in lipids to allow for gradual release of the analgesic over a 72-hour period (NAMDARI). From prior literature, the utilization of local analgesics infiltrated into surgical sites have been shown to reduce pain in the immediate post-operative period in foot and ankle surgery (GADEK). However, the evaluation of liposomal bupivacaine in foot and ankle surgery is limited. One prospective study found that the addition to liposomal bupivacaine to a multi-modal pain management protocol for forefoot surgery resulted in decreased pain scores during the first four post-operative days as well as fewer refills of opioid pain medication prescriptions, although both findings were not statically significant (ROBBINS). As the general medical community and public policy makers continue to focus on decreasing the amount of opioid pain medications prescribed and available in the community due to the opioid epidemic, liposomal bupivacaine has the potential to be a useful adjunct in the management of post-operative pain without reliance on opioid prescriptions. The goal of this investigation is to compare the efficacy of local administration of liposomal bupivacaine versus the efficacy of a peripheral nerve block in terms of post-operative pain scores after elective ankle and hindfoot surgery. The investigators hypothesize that there will not be a significant difference in the pain scores of these two groups in opioid naïve patients. Furthermore, this study aims to determine if there are differences in the amount of opioid medications utilized for post-operative pain control, patient satisfaction scores, functional outcomes, complications, and unscheduled healthcare contact between the two groups. In order to accomplish these aims, a randomized, controlled investigation will be conducted.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients 18 years of age or older
- •Patients undergoing elective primary ankle or hindfoot surgery (ankle arthrodesis, subtalar arthrodesis, triple arthrodesis, total ankle arthroplasty, peroneal tendon debridement/transfer, Cavus Reconstruction, Medial Displacement Calcaneal Osteotomy, Dwyer Osteotomy)
Exclusion Criteria
- •Patients who are undergoing revision surgical procedure
- •Patients who have taken opioid pain medications in the past 3 months prior to surgical procedure
- •Patients who have allergies to any of the medications or components of medications investigated in the study
- •Patients currently incarcerated
- •Patients who cannot read and speak English
Arms & Interventions
Liposomal Bupivacaine Group
No peripheral nerve block will be given. Local infiltration of 20cc of Liposomal Bupivacaine infiltrated to the surgical area.
Intervention: Liposomal bupivacaine
Peripheral Nerve Block Group
Peripheral Nerve Block performed by anesthesia team (blocks will be given by same anesthesia provider utilizing same technique every time in order to reduce variations in delivery of peripheral nerve block). No local analgesic agent infiltration
Intervention: Peripheral Nerve Block
Outcomes
Primary Outcomes
Visual Analog Scale Pain Score
Time Frame: Baseline and 6 weeks
Best 0-10 worst - Continuous scale to measure current pain level
Secondary Outcomes
- Morphine Equivalents(0-6 weeks)
- Range of Motion(0-6 weeks)
- Investigator-developed, Pain Satisfaction Score(0-6 weeks)
- Number of Participants With Complications(6 weeks)
- Number of Participants With Unscheduled Healthcare Contact(6 weeks)